The taxanes Docetaxel and Paclitaxel are two of the standard chemotherapies for patients with metastatic breast cancer. The functional effect of Docetaxel and Paclitaxel on human innate immune cells of the myeloid lineage is not well established, nor is the effects these agents have on differentiation of monocytes into macrophages and dendritic cells. Therefore, the aim with this project was to determine the effects of Docetaxel and Paclitaxel on primary human monocyte differentiation, activation and function. For this purpose, primary human monocytes were isolated from healthy donors and cultured with or without Docetaxel and Paclitaxel. We found that Docetaxel promoted the differentiation of primary human monocytes into pro-inflammatory macrophages with an M1 phenotype and an ability to present antigens to T cells. Monocytes treated with Docetaxel also displayed an elevated secretion of IL-8 and IL-1β, but did not promote generation of monocytic myeloid-derived suppressor cells. In conclusion, Docetaxel appears to have an immune stimulatory effect that would be beneficial for an antitumorigenic type of immune response, whereas Paclitaxel seems to have less effect on myeloid cells.
Introduction
Macrophages and dendritic cells are antigen-presenting cells (APCs) that bridge the innate and adaptive immune system by presenting antigens to T cells. In response to inflammation or infection, monocytes migrate into the inflamed tissue and differentiate into either monocytederived macrophages (Mo-M) or monocyte-derived dendritic cells (MoDCs). The differentiation of monocytes is a plastic process that is determined by the local environment [1, 2] .
Macrophages are a heterogeneous population of cells with a great plasticity that in its extreme forms can attain a pro-inflammatory (M1) or an anti-inflammatory (M2) phenotype depending on the local environment. M1 macrophages produce pro-inflammatory cytokines, have a high capacity to present antigens, and effectively kill microorganisms and tumor cells. In contrast, M2 macrophages suppress the inflammatory response through production of anti-inflammatory mediators, and promote angiogenesis, tissue remodeling and repair. Tumor associated macrophages (TAMs) are most often viewed as M2-like macrophages, that are controlled by the tumor microenvironment to differentiate and mature from recruited monocytes into M2-like cells [3] [4] [5] .
Monocytic myeloid-derived suppressor cells (Mo-MDSCs) are monocytic cells with strong immunosuppressive properties that are enriched in cancer patients [6] . These cells have been proposed to originate from monocytes through a process called reprogramming that is regulated by the environment, and important cytokines for this process are GM-CSF, IL-6, and IL-10 [6, 7] . The elimination of MDSCs in cancer patients and mice dramatically improves the immune response [8] [9] [10] .
Taxanes are clinically important drugs in the treatment of various cancers, including breast cancer. Two of the most frequently used Taxanes in the clinic are Docetaxel (Taxotere) and Paclitaxel (Taxol) and these agents are two of the standard chemotherapies for patients with metastatic breast cancer [11, 12] .
Taxanes exert an anti-tumor activity by binding to β-tubulin, thus stabilizing microtubule structures resulting in cell cycle arrest at the G2-M mitotic phase and finally cell death [12] . Despite this effect, Docetaxel and Paclitaxel have been demonstrated to have immune stimulatory functions by stimulating anti-tumorigenic mechanisms in mice [12] [13] [14] [15] . For instance, Docetaxel and Paclitaxel suppress MDSCs, while promoting their differentiation into macrophages and dendritic cells, which may contribute to the overall anti-tumorigenic effects [14, 15] . In addition, Docetaxel and Paclitaxel have been shown to induce the secretion and production of pro-inflammatory mediators such as IL-1, COX-2, and IL-12 [13, 16] . Paclitaxel was also found to mimic the action of LPS by inducing the maturation of mouse macrophages and dendritic cells, which led to the finding that this chemotherapeutic agent binds and signals through Toll-like receptor 4 (TLR4) [17] [18] [19] .
Most studies concerning the immune stimulatory functions of Docetaxel and Paclitaxel have been conducted in mice or using mouse cells. Although there are studies performed using human cells as well, there are interspecies differences reported. For instance, Taxane induced HLA-DR expression on dendritic cells was attributed by TLR4 in mice, but not in humans [17, 19, 20] . Indeed, the effect of Docetaxel and Paclitaxel on primary human monocyte differentiation per se has not been demonstrated previously. Therefore, further studies on how Docetaxel and Paclitaxel exert their effects on primary human innate myeloid cells is needed to establish how the treatment with these agents affects the patient's immune system. When Docetaxel or Paclitaxel are given as treatment to cancer patients, these agents are administrated intravenously. Thus, Docetaxel and Paclitaxel have the ability to influence the differentiation and activation of naïve monocytes both in the circulation, as well as in tissues of patients. In this study we explored how Docetaxel and Paclitaxel affected the differentiation, activation and function of monocyte derived macrophages and dendritic cells in vitro.
Materials and methods

Isolation of monocytes and CD4
+ T cells 
Cell culture
Monocytes were cultured in RPMI-1640 (HyClone, GE Healthcare Life Science, Logan, UT, USA) supplemented with 10% human serum, 100 U/ml pencillin, 100 µg/ml streptomycin (MP Biochemicals, Solon, OH, USA), and 10 ng/ml recombinant GM-CSF (R&D systems, Minneapolis, MN, USA) at a concentration of 1 × 10 6 cells/ml.
Monocytes were cultured in GM-CSF to induce myeloid cell survival and allow differentiation into both unpolarized monocyte derived macrophages, as well as some monocyte derived dendritic cells [21] . This setting was used to allow for an autocrine effect of potential chemo-induced cytokines. The cells were stimulated with or without Docetaxel or Paclitaxel for 48 h or 120 h at 37°C in a humidified air atmosphere with 5% CO 2 . Cells were harvested using non-enzymatic cell dissociation solution (Sigma Aldrich, St. Louis, MO, USA).
Flow cytometry analysis
Flow cytometry analyses were performed on a FACSVerse (BD Bioscience, San jose, CA, USA) and analyzed with FlowJo software (Tree Star Inc., Ashland, OR, USA). All antibodies (Abs) were titrated before used. For staining, cells were incubated with Abs for 20 min, washed and resuspended in FACS buffer (PBS supplemented with 3% FBS and 0.1% NaN 3 ) prior to analysis. The following Abs were purchased from BD Bioscience: HLA-DR-FITC (L243), CD1a-PE (HI149), CD14-PerCP-Cy5.5 (M5E2), CD86-PE-Cy7 (2331 [FUN-1]), and CD206-APC (19.2).
Cytokine bead array (CBA)
Supernatants from cultured monocytes were collected and levels of cytokines were measured using Human inflammatory cytokine cytometric bead array (BD Bioscience), according to instruction of the manufacturer. The following cytokines were measured: IL-8 (Limit of detection 3.6 pg/ml), IL-1β (7.2 pg/ml), IL-6 (2.5 pg/ml), IL-10 (3.3 pg/ml), TNFα (3.7 pg/ml), and IL-12p70 (1.9 pg/ml). Cytokine levels were then detected using a FACSCalibur from BD Bioscience.
Allogeneic mixed leukocyte reaction (MLR)
The monocytes cultured with or without Docetaxel or Paclitaxel for 7 days were harvested with non-enzymatic cell dissociation solution and reseeded in 96-well plates with 10,000 freshly Naïve CD4 + T cells at stimulator-responder ratio 1:1, 1:10, and 1:100. As positive control T cells were stimulated with T cell activating CD3/CD28 Dynabeads (Gibco, Thermo Fisher Scientific, Waltham, MA, USA). Proliferation of the responding T cells was quantified by 1 µCi [methyl-3 H]-thymidine after 6 days including an 18 h pulse period and the incorporation was determined in a Microbeta Counter (PerkinElmer, Waltham, MA, USA).
Endocytosis assay
The endocytosis activity of Docetaxel or Paclitaxel treated myeloid cells was assessed by FITC-dextran uptake. After 120 h of cultivation, the cells were incubated with 1 mg/ml FITC-dextran (Sigma Aldrich) for 20 min at 37°C and subsequently harvested. This was followed by an incubation for 20 min with CD1a-PE, CD14-PerCP-Cy5.5, CD86-PECy7, and CD206-APC Abs and the uptake was analyzed by flow cytometry. As control for endocytosis, cells were incubated at 4°C.
Statistics
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA) and data are presented as mean ± standard error of the mean (SEM). n is equal to the number of independent donors and p-values of ≤ 0.05 was considered statistically significant. The nonparametric Friedman test with Dunn's post test was used for multiple comparison of paired data.
Results
Docetaxel promotes a M1 phenotype
We first started by determining the effect of Docetaxel and Paclitaxel on the in vitro differentiation of monocytes into Mo-M and Mo-DCs after 120 h. We found indications that, Docetaxel increased the generation of M1 macrophages, and slightly decreased the percentage of M2 macrophages. In contrast, Paclitaxel did not affect the differentiation of M1 and M2 macrophages (Fig. 1A) . See Fig. 1C Docetaxel and Paclitaxel did not have any effect on the differentiation of monocytes into Mo-DCs or the maturation of these cells (Supplemental Fig. S1 ). For gating strategy see Fig. 1D . DR high ). The same was seen using Paclitaxel although less apparent (Fig. 1B) . Gating strategy is found in Fig. 1E . In line with the increase in Mo-M (CD14 + HLA-DR high ) cells, we found that CD14 + cells overall had an elevated expression level of HLA-DR after 120 h of cultivation with Docetaxel or Paclitaxel (Fig. 2A) . The CD14 + cells also displayed an elevated level of the activation marker CD86 after 120 h of stimulation ( Fig. 2A) , as did the Mo-M cells (Fig. 2B) . Thus, both Docetaxel and Paclitaxel seem to promote activation of the cultured monocytes and monocyte derived macrophages in vitro.
Docetaxel activates M1 macrophages
Since Docetaxel promoted the differentiation of monocytes into M1 macrophages, the activation of these cells was determined after the monocytes had been stimulated for 48 h and 120 h with Docetaxel or Paclitaxel. After 48 h, Docetaxel increased the expression level of HLA-DR on M1 macrophages (Fig. 2C) , whereas no effect on CD86 was detected. Both HLA-DR and CD86 expression levels were increased after 120 h of stimulation with Docetaxel (Fig. 2D) . In contrast, Paclitaxel did not have any pronounced effect on the expression of HLA-DR or CD86 on M1 macrophages at either time point (Fig. 2C and D) . Overall, this suggests that Docetaxel may promote M1 macrophage activation. 
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Docetaxel increases monocyte secretion of IL-8
The local environment and the initial inflammatory cytokine secretion profile induced by Docetaxel and Paclitaxel on primary human monocytes was determined after merely 18 h. Docetaxel induced the secretion of IL-8 and IL-1β. Paclitaxel did not appear to have any pronounced effect on any of the cytokines investigated, except for the higher Paclitaxel concentration of 10 µM that had some effect on IL-1β (Fig. 3) .
An increased antigen presentation was detected after Docetaxel stimulation
To determine whether Docetaxel or Paclitaxel would affect the function of CD14 + cells (composed of a mixture of monocytes, Mo-M and Mo-DCs (APCs) and Mo-MDSCs), we investigated their endocytosis capacity by measuring FITC-Dextran uptake, and their ability to activate T cells through an allogeneic MLR. Docetaxel appeared to decrease the endocytosis capacity of APCs, whereas Paclitaxel had no distinct effect (Fig. 4A ). In addition, the lower amount of Docetaxel pretreated myeloid cells (myeloid-T cell ratio 1:100) actually increased the T cell stimulatory capacity compared to unstimulated myeloid cells at the same ratio as measured by allogeneic MLR (left graph Fig. 4B ). This was visualized when the myeloid-T cell ratio 1:100 was divided with the 1:1 ratio (right graph Fig. 4B ). In contrast, Paclitaxel had no distinct effect on the antigen presentation function. As positive control T cells were stimulated with activating CD3/CD28 beads (Fig. 4B) . This suggests that Docetaxel may induce the ability of antigen presenting cells to present antigens to T cells.
Discussion
In this study, we have demonstrated that Docetaxel not only affects the activation and function of human myeloid cells as previously shown [16, 23] , but also induce a supposedly beneficial pro-inflammatory response as demonstrated by an increased differentiation of primary 
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human monocytes towards M1 macrophages and a decreased generation of Mo-MDSC-like cells. Our results are supported by previous findings that Docetaxel induces the differentiation of MDSCs into M1 macrophages in mice [14] , and that Paclitaxel induces the differentiation of MDSCs into DCs [15] . Mo-MDSCs are anti-inflammatory cells with tumor promoting properties that inhibit T cells [6] , while M1 macrophages have an anti-tumorigenic function per se [24, 25] and the ability to induce a Th1 response that can generate and augment a tumor specific cytotoxic T lymphocyte (CTL) reaction [26] . Cancer patients with a high number of MDSCs have a decreased overall survival and a decrease in MDSCs after therapy leads to tumor regression [10, [27] [28] [29] . Furthermore, patients with a higher level of tumor infiltrating M1 macrophages have a better overall survival [30] [31] [32] . Altogether, this suggests that in particular Docetaxel may promote an anti-tumorigenic immune response, by reducing the Mo-MDSCs like cell population and inducing M1 macrophage polarization simultaneously.
There are several studies strongly suggesting that both Docetaxel and Paclitaxel have immune stimulatory functions. These studies have been performed both in mice and in humans, mostly using Paclitaxel [19] . Our studies confirm what has previously been shown regarding activation of myeloid cells, but with the addition that Docetaxel induces an activation of the human pro-inflammatory M1 macrophages. This is of importance with regards of being able to evoke a sufficient activated anti-tumor immune response also in the presence of treatment with chemotherapy.
It is important to recognize that a high concentration of Docetaxel has been shown to have negative effects on leukocytes by for instance suppressing the motility and inducing apoptosis of human DCs [23] . As monotherapy for treatment of cancer patients Docetaxel is given at a concentration of 100 mg/m 2 , which is equal to a maximal blood concentration of 2-7 µM [33] [34] [35] , indicating that the concentrations used in this study (0.1-10 µM) covers the proposed patient dose range, but that the concentration 10 µM might be in the higher range.
In our study, Docetaxel potently induced the secretion of IL-8, and slightly IL-1β, by primary human monocytes. The pro-inflammatory cytokine IL-1β is a classical M1 cytokine that enhances the expansion and differentiation of T helper cells [36, 37] , thus further supporting the finding that Docetaxel seem to favor a M1 macrophage polarization. The pro-inflammatory cytokine and neutrophil chemoattractant IL-8, is one of the earliest cytokines detected during inflammation or infection and is mainly produced by activated monocytes and macrophages. Cancer cells, TAMs, tumor infiltrated neutrophils, and endothelial cell can also produce IL-8. Besides recruiting neutrophils, IL-8 has angiogenetic properties and may potentiate migration and survival of tumor cells in the tumor microenvironment [38, 39] . In breast cancer, the expression of IL-8 by the malignant cells is related to hormone receptor negative status on the malignant cells [40] . The enhanced level of IL-8 detected after Docetaxel treatment in patients, should consequently be considered by reflecting both an abrupt activation of circulating monocytes systemically, but also its angiogenic effect in the tumor or tissues per se.
Except for interspecies variations regarding Paclitaxel's enrollment of TLR4 between mice and human, dose dependent response differences have also been described. The differentiation of MDSCs into DCs in mice have been demonstrated to be TLR4-independent when the MDSCs were treated with a low dose of Paclitaxel (1 nM), whereas the maturation of DCs were shown to be TLR4-dependent when the cells were stimulated with Paclitaxel in the µM range [15, 17, 19] . This interspecies and dose dependent variations can explain why we see a lower effect of Paclitaxel than previously reported.
Endocytosis and antigen presentation by APCs are two important steps for the induction of tumor specific CLTs. These processes are separated in time, as endocytosis mostly engages immature cells that are scanning the environment for foreign patterns, whereas antigen presentation is a sign of maturation. Endocytosis and recognition of foreign patterns provokes a maturation process of the endocytosing myeloid cells that subsequently gains the capability of antigen presentation to T cells in secondary lymphoid organs [22] . As Docetaxel appears to decrease the endocytosis capacity while increasing that of antigen presentation of the primary human myeloid cells, this would be in line with the finding that Docetaxel induces activation of the myeloid cells in our cultures. Another similar explanation could be that M1 macrophages are superior APCs than M2 macrophages, and vice versa for endocytosis [41] . These findings further support the notion that Docetaxel treated myeloid cells may have an increased ability to generate a tumor specific T cell response. In addition, Docetaxel appears to have more effect on myeloid cells than Paclitaxel. These two therapeutic agents most likely have more functions that have not yet been identified. Hence, this study is a piece of the puzzle in understanding the anti-tumorigenic functions of Docetaxel and Paclitaxel.
